Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.
Notably, in multiple studies presented at this year's EHA Annual Congress, the third-generation tyrosine kinase inhibitor (TKI) olverembatinib showed broad therapeutic potential and demonstrated particular clinical benefit in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). According to the results, olverembatinib demonstrated high complete remission (CR) and complete molecular response (CMR) rates, as well as favorable tolerability in the first-line treatment of newly diagnosed and relapsed/refractory Ph+ ALL, and specific subtypes of some hematologic malignancies (e.g., myeloid/lymphoid neoplasm with FGFR1 rearrangement). Furthermore, studies on various combinations of olverembatinib (with venetoclax plus azacitidine, the VP regimen, blinatumomab, or inotuzumab ozogamicin) have shown encouraging results that revealed olverembatinib's potential in offering more treatment options and improved long-term prognoses to patients with Ph+ ALL.
In addition, a preclinical study of the investigational EED inhibitor APG-5918, another key asset in Ascentage Pharma's pipeline, was featured in a poster presentation at the Congress. These data showed the potent antitumor activity of APG-5918 in T-cell lymphoma and support further clinical development of the agent.
Highlights of select abstracts presented at EHA 2025 are as follows (for detailed results from all 13 studies of the company's assets, please visit the official EHA website):
Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia
Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial
Efficacy and Safety of the Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study
A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in Preclinical T-Cell Lymphoma (TCL) Models
*Olverembatinib and APG-5918 are investigational compounds and have not been approved by the U.S. FDA.
About Ascentage Pharma
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.
The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.
The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response, as well as global registrational Phase III trials for patients with newly diagnosed CLL/SLL, AML, and MDS.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations:
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
[email protected]
+86 512 85557777
Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
SAN JOSE, Calif., June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT. During the webcast, Dr. Amit Kumar, Anixa's Chairman and CEO, will conduct an introductory presentation that will cover key aspects of Anixa's business including an overview of the Company's therapeutic portfolio, its business strategy, market opportunity and near-term milestones. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal. To listen to the webcast or to ask questions during the live event, please pre-register at the following link: An archived version of the webcast and presentation will be available on the Company's website, About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
an hour ago
- Yahoo
China's Rare Earth Magnet Exports Slump in May, Especially to US
(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here. Security Concerns Hit Some of the World's 'Most Livable Cities' One Architect's Quest to Save Mumbai's Heritage From Disappearing JFK AirTrain Cuts Fares 50% This Summer to Lure Riders Off Roads NYC Congestion Toll Cuts Manhattan Gridlock by 25%, RPA Reports Taser-Maker Axon Triggers a NIMBY Backlash in its Hometown Chinese exports of rare earth magnets slumped further in May, with shipments to the US showing an especially steep drop due to the trade war with Washington. Rare earth minerals, and the products that use the elements, have been at the center of the dispute since early April, when China imposed export controls in retaliation for punitive tariffs levied on Chinese goods. The two countries have since sought to reset relations, culminating in a meeting in London in early June, which prompted US President Donald Trump to declare that issues around rare earths had been resolved. China accounts for about 90% of the world's rare earth products, most of which are magnets, and whether it allows supplies to flow more freely after the agreement reached in London will be a key focus for governments and markets in the weeks and months to come. Chinese customs data on Friday showed the extent of the impact on supplies of rare earth magnets in particular, an item vital for high-tech industries from carmakers to defense contractors. The controls have affected sales to all countries, with China's total exports roughly halving in April, and then halving again in May, to 1,238 tons. That comes to about $60 million, the lowest-value month in data going back to 2015, barring February 2020 and the onset of the pandemic. The US portion by volume in May was just 46 tons, less than one-tenth of the magnets it imported in March. Other countries including Vietnam, host to a number of Chinese companies, and Germany saw their supplies hold up much better. Those two countries were the top destinations last month, accounting for 19% and 17% of sales, respectively. --With assistance from James Mayger. Ken Griffin on Trump, Harvard and Why Novice Investors Won't Beat the Pros Is Mark Cuban the Loudmouth Billionaire that Democrats Need for 2028? The US Has More Copper Than China But No Way to Refine All of It Can 'MAMUWT' Be to Musk What 'TACO' Is to Trump? Luxury Counterfeiters Keep Outsmarting the Makers of $10,000 Handbags ©2025 Bloomberg L.P.
Yahoo
an hour ago
- Yahoo
7 Items To Stock Up on in Response to Trump's Tariffs
In the politically tumultuous world of looming inflation, you have to start asking yourself what to stock up on in response to price hikes. Do you purchase items from Canada, Mexico or China? Read Next: Learn More: The Trump Administration has placed an additional 25% tariff on imports from Canada and Mexico and an additional 10% tariff on imports from China, according to the White House's official website. These tariffs are on top of existing tariffs already in place — so how could this affect consumers' personal finances? There has been a lot of back and forth with the tariff mandates, but ultimately, it comes down to how much each will impact your wallet. Here are some examples: Homes: The National Association of Home Builders (NAHB) estimated that before the recent 50% tariffs on steel and aluminum, tariff activity added roughly $10,900 to the average cost of a new home. This could also reduce the number of homes being built, which would create a housing shortage, and lead to higher inflation pricing thanks to warped supply and demand. Car: Some economists predict that Trump's Tariffs are expected to drive up auto costs anywhere between $4,000 to $12,500, depending on what type of car you buy and where it comes from. For example, there is an imposed 25% tariff on steel and aluminum that could hurt U.S. automakers on imports from Mexico and Canada. Food: Coffee from Brazil (tariff rate: 10%) and Colombia (tariff rate: 10%); Olive Oil from anywhere in the European Union (tariff rate: 20%); Seafood from Chile (tariff rate: 10%), India (tariff rate: 26%), Indonesia (tariff rate: 32%) and Vietnam (tariff rate: 46%); Fruit from Guatemala (tariff rate: 10%), Costa Rica (tariff rate: 10%) and Peru (tariff rate: 10%) In an ideal world, these tariffs wouldn't increase the price for U.S. consumers; however, this isn't realistic. With that in mind, try to make some intentional purchases for items now that are subject to Trump's tariffs and will go up in price, if they hopefully haven't already. Here are a few things to add to your shopping list to grab before stores have to restock with more expensive inventory. For You: Countless well-known computer brands, such as Apple, Dell and HP, create and assemble their products in China. According to the Observatory of Economic Complexity (OEC), 8.7% of all exports from China are for computers. If you're thinking about upgrading your work laptop or gaming PC, consider doing so now before prices are adjusted for tariffs. TV and other broadcasting equipment accounted for 12.5% of exports from China to the United States, according to the OEC. Have you been dreaming about a 75-inch flatscreen TV in your living room? How about upgrading your desk monitors or investing in a surround sound system? Whatever the case, consider buying your TV and electronics equipment now. China is a major exporter of toys and video games to the United States. In 2023, toys, video games and card games accounted for 5.40% of imports into the United States, per the OEC. Now might be a great time to stock up on birthday presents, Christmas gifts and other toy items before prices increase. If you're a business owner or in the market for a new vehicle, consider expediting your purchase. Over 23% of imports from Mexico in 2023 were related to cars, delivery trucks and accessories, according to the OEC. If you've been considering upgrading your car, it might make sense to get the process started sooner rather than later. If you enjoy having a cold one after a long day, check where your beverage comes from. In 2023, purchases of beer and hard liquor made up 2.32% of the United States' imports from Mexico, per the OEC. Alcoholic beverages have a long shelf life, making them great items to stock up on. Canada is a major producer of rapeseed oil, also known as canola oil. In fact, 1.18% of all U.S. imports from Canada in 2023 were for rapeseed oil, according to the OEC. If canola oil is your preferred cooking oil, consider stocking up, as prices are likely to increase due to tariffs. Wood products, including sawn wood, particleboard board and wood carpentry items, made up 2.25% of imports from Canada in 2023, per the OEC. If you're considering starting a new project or ordering a new piece of furniture, now might be the time to stock up. The prices for lumber and products containing wood and particleboard may increase over the next few months. New tariffs don't always mean prices will increase. However, taking a proactive approach and stocking up on items you would already be purchasing can safeguard your wallet if prices do rise. Caitlyn Moorhead contributed to the reporting for this article. Editor's note on political coverage: GOBankingRates is nonpartisan and strives to cover all aspects of the economy objectively and present balanced reports on politically focused finance stories. You can find more coverage of this topic on More From GOBankingRates 7 Luxury SUVs That Will Become Affordable in 2025 This article originally appeared on 7 Items To Stock Up on in Response to Trump's Tariffs
